for months i kept reading certificates of analysis for a healing blend a lot of people research, the ghk-cu / kpv / bpc-157 stack that ships with "TB-500" on the label. and every time, in the net peptide content, where i expected the line to read TB-500, the lab had written something else: thymosin beta-4.
the first time, i figured it was a typo, someone in the testing queue typing the famous parent protein instead of the fragment on the label. then i saw it on the next COA. and the next. different products, different labs, the same swap. so i stopped assuming it was a mistake and went digging. here is the disparity, and why it actually matters.
"TB-500" was never thymosin beta-4.
by its original definition, TB-500 is a fragment of thymosin beta-4: the seven-amino-acid Ac-LKKTETQ sequence, about 889 daltons. a WADA-accredited lab at Ghent pinned that down by mass spectrometry in 2012. full-length thymosin beta-4 is a different animal, 43 amino acids, about 4,963 daltons. five times the mass, two different molecules wearing one name.
what's probably actually in the vial.
when an anti-doping lab ran real "TB-500" products through mass spec in 2023, the contents were, in their words, "not systematically consistent" with the labels. some vials held the 889-dalton fragment. others, labeled identically, held full 43-amino-acid thymosin beta-4. a separate product analyzed alongside it was mostly sheep extracellular matrix. so the answer to "is the TB-500 i'm getting actually thymosin beta-4?" is: a lot of the time, yes, and the mass on the COA is how you know.
the full protein, but not for the reason people say.
the full protein is the more complete, better-characterized molecule, the form every clinical program was built on. but it is not "more potent." in the lab test that defines its activity, new blood-vessel growth (angiogenesis), the isolated active fragment (the LKKTETQ sequence) and the full protein work at roughly the same strength, active at about 50 nanomolar, an extremely low concentration. so if a vial labeled TB-500 assays as full thymosin beta-4, it is the more data-driven version, not a stronger one.
and "more data-driven" still has a ceiling. thymosin beta-4 has a deep preclinical record across skin, cornea, heart, and brain. its human trials are a run of misses: the dry-eye phase 3 ARISE-3 missed, the neurotrophic-keratopathy phase 3 SEER-1 missed at p=0.0656, and the european SEER-3 missed in june 2026. the injectable cardiac trial never enrolled a patient. it is approved as a drug nowhere, for nothing. on this site it sits at A tier, graded on real biology and a human record that hasn't closed, and it stays there.
everyone says "tb-500."
Derek of More Plates More Dates rattles off "BPC-157, TB-500, ipamorelin" on the Joe Rogan Experience (#2239). Andrew Huberman names it on his own show, though he is careful to call it "a truncated version of thymosin beta-4." the BPC-157 + TB-500 "wolverine stack" is a podcast and biohacker fixture. they all say "TB-500." what is actually in the vial varies, fragment or full protein, and only the COA mass says which.
this teaser is the short version. the deep-dive is the whole case: the redacted COA up close, every RegeneRx human trial and why the late-stage ones missed, the PMID-checked mechanism, the grade rationale, and how to read the mass on a COA so the label and the contents actually agree.
read the deep-dive →part of paid access · $100 once, lifetime accessreptides editorial · research reference, not medical advice.